RTTNews BiotechDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 15:16:20(美东 03:16)·⟳ 抓取 15:16:24 +4s·⚡ 决策 10-21 22:52:43 +7h36m·6.1 天前
英矽智能（3696.HK）与施维雅合作达成首个早期药物发现里程碑，触发金额未披露的里程碑付款
同一具体催化（Servier首个早期发现里程碑、金额未披露）已于2026-10-20由港交所自愿公告首发，并被本臂三个信源（hkex公告、界面、星岛）先后处理且均判不做；本条RTTNews仅为次日英文媒体转述，事实完全相同、无新增金额或指引。且10-21股价高开低走收跌2.13%，软催化已被消化，20日跌39.6%处下行通道，无剩余edge。
📄 原文RTTNews Biotech↗ 原文
Insilico Medicine Hits Discovery Milestone In AI-Driven Oncology Partnership With Servier
Insilico Medicine Cayman TopCo (3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discover…
不做 英矽智能（03696.HK）
重复旧闻无新增事实：该里程碑系10-20港交所自愿公告内容、已被三次处理；付款金额未披露且处最早期靶点提名阶段，对226亿港元市值量级微小；10-21高开+4.2%后收跌2.13%已见光死，20日-39.6%强下行通道，追多无正期望；事件非实质利空，不满足做空红线。若后续披露里程碑金额超预期或新增MNC大额合作再重估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这是10月20日港交所公告的旧闻转述：最早期靶点提名里程碑、付款金额未披露，对约226亿港元市值无实质增量；公告次日高开4.2%后收跌2.13%已完成见光死定价，不做。
🔎 新鲜度:最早出现 2026-10-20 · 扩散 high · price-in 风险 high ↗
主要风险
- 若公司后续披露该里程碑金额显著超预期（达数千万美元级），或宣布新的MNC大额合作，需重新评估
- 个股20日跌39.6%、距52周高点-52%，下行趋势中任何软催化追多均面临持续抛压
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-21 · 影响 weakens
本臂10-20已核查：20日跌约27%（现扩大至-39.6%），10-13同类公告日跌7.8%，10-21本公告高开低走；无超预期金额披露，软催化在强下行趋势中无正期望
检索:3696.HK 近期利空 砍单 下行 里程碑金额
先例如何影响了这次决策
对本次决策的影响:确认AVOID：不追多；事件非利空，亦不满足做空红线
方向:同一催化已有三次本臂即时研判，且公告次日真实价量给出最直接的对齐证据：高开低走收跌2.13%
涨幅量级:无需外部先例：软催化、金额未披露，且标的自身公告次日反应即为负；不支持任何正期望幅度
形态:10-13同类研发公告日-7.82%、10-21本公告次日高开低走-2.13%，反复出现利好不涨/见光死形态
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,650 ms
{"result": "search_processed_events:agent query=`insilico medicine servier oncology milestone 3696.hk | insilico pharma.ai drug discovery milestone payment | 英矽智能 施维雅 肿瘤 里程碑付款`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.9/72 小时、23469 条本臂决策(完整)，返回 3 条候选。\n• 10-20 00:17 UTC(北京 08:17) [bm25:91%,ticker] 不做 3696.HK (hk - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 1,192 ms
{
原文全文
展开原文 · 2,723 字
Insilico Medicine Cayman TopCo (3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has achieved an early drug discovery milestone in its multi-year AI-driven drug discovery collaboration with Servier, an independent international pharmaceutical group governed by a foundation.
The collaboration, announced in early 2026, combines Insilico's artificial intelligence-based drug discovery platform with Servier's oncology research and development capabilities to identify and advance novel small-molecule therapies against selected cancer targets.
Under the agreement, Insilico will lead AI-driven discovery and early-stage development, while Servier will share R&D costs and oversee later-stage clinical development and potential commercialisation. The deal includes up to $888 million in potential payments, including $32 million in upfront and near-term R&D funding.
Under the collaboration, the companies initiated two oncology research programs targeting challenging disease pathways using Insilico's proprietary Pharma.AI platform. They have also completed target nominations for both programs.
Insilico has reached the early drug discovery milestone for the first program. The milestone triggers an undisclosed milestone payment from Servier to Insilico.
"I am glad to see that within 10 months of launching our collaboration, we identified and initiated 2 programs under the collaboration" said Alex Zhavoronkov, founder, CEO and CBO of Insilico Medicine.
Insilico's total revenue was approximately $106 million for the first half of 2026, representing a year-over-year increase of 287%, alongside an adjusted net profit exceeding $51 million, marking its first profitable half-year since listing.
The strong first-half financial performance was driven primarily by a series of out-licensing agreements, co-development arrangements, and research and development collaborations with industry partners, including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygeia Therapeutics, China Medical System (CMS), and Tenacia Biotechnology.
3696.HK has traded between HK$29.98 and HK$80.90 over the last year. The stock is currently down 2.38% at HK$38.50.
For more biotech stock news, visit www.rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
The collaboration, announced in early 2026, combines Insilico's artificial intelligence-based drug discovery platform with Servier's oncology research and development capabilities to identify and advance novel small-molecule therapies against selected cancer targets.
Under the agreement, Insilico will lead AI-driven discovery and early-stage development, while Servier will share R&D costs and oversee later-stage clinical development and potential commercialisation. The deal includes up to $888 million in potential payments, including $32 million in upfront and near-term R&D funding.
Under the collaboration, the companies initiated two oncology research programs targeting challenging disease pathways using Insilico's proprietary Pharma.AI platform. They have also completed target nominations for both programs.
Insilico has reached the early drug discovery milestone for the first program. The milestone triggers an undisclosed milestone payment from Servier to Insilico.
"I am glad to see that within 10 months of launching our collaboration, we identified and initiated 2 programs under the collaboration" said Alex Zhavoronkov, founder, CEO and CBO of Insilico Medicine.
Insilico's total revenue was approximately $106 million for the first half of 2026, representing a year-over-year increase of 287%, alongside an adjusted net profit exceeding $51 million, marking its first profitable half-year since listing.
The strong first-half financial performance was driven primarily by a series of out-licensing agreements, co-development arrangements, and research and development collaborations with industry partners, including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygeia Therapeutics, China Medical System (CMS), and Tenacia Biotechnology.
3696.HK has traded between HK$29.98 and HK$80.90 over the last year. The stock is currently down 2.38% at HK$38.50.
For more biotech stock news, visit www.rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
6c839c656e· 2026-10-21 22:52 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前